|
h-R3 MAb combined with radio chemotherapy to treat non-surgical esophagus tumors of epithelial origin. |
|
Intraoperative endoscopic retrograde sphincterotomy as a modality of treatment of choledocholithiasis |
|
hR3 MaB and radiotherapy in highly malignant astrocytic tumors, phase III. |
|
h-R3 MaB and radiotherapy in pediatric patients with intrinsic diffuse astrocytomas of brain stem, phase II. |
|
Anti-idiotype 1E10 vaccine in the treatment of patients with small cell lung (SCLC) patients |
|
Anti-idiotype 1E10 vaccine in advanced non- small cell lung (NSCLC) patients |
|
1E10 anti-idiotype vaccine, metastatic breast cancer, phase II |
|
Toxicological evaluation of the humanized Anti-CD6 MAb T1h in Rheumatoid Arthritis Patients |
|
1E10 anti-idiotype vaccine, metastatic colon, phase II. |
|
Evaluation of the neuroprotector effect of an extract of stem bark of Mangifera indica L. (Vimang®) in patient with Spinocerebellar Hereditary Ataxia Type 2 |
|
Extract of Mangifera indica L. (Vimang®)-Ischemic Stroke |
|
Extract of Mangifera indica L. (Vimang®)- Third age- Phase II. |
|
Effect of the supplementation with Vimang ® on indicators of oxidative stress in young people with Diabetes Mellitus type 1. |
|
Evaluation of the antiinflammatory effect of the Vimang® cream in patients with Dermatitis chronic disease. |
